title: Ribosomal protein L5 helps anchor peptidyl-tRNA to the P-site in Saccharomyces cerevisiae.
abstract: Our previous demonstration that mutants of 5S rRNA called mof9 can specifically alter efficiencies of programmed ribosomal frameshifting (PRF) suggested a role for this ubiquitous molecule in the maintenance of translational reading frame, though the repetitive nature of the 5S rDNA gene (>100 copies/cell) inhibited more detailed analyses. However, given the known interactions between 5S rRNA and ribosomal protein L5 (previously called L1 or YL3) encoded by an essential, single-copy gene, we monitored the effects of a series of well-defined rpl5 mutants on PRF and virus propagation. Consistent with the mof9 results, we find that the rpl5 mutants promoted increased frameshifting efficiencies in both the -1 and +1 directions, and conferred defects in the ability of cells to propagate two endogenous viruses. Biochemical analyses demonstrated that mutant ribosomes had decreased affinities for peptidyl-tRNA. Pharmacological studies showed that sparsomycin, a peptidyltransferase inhibitor that specifically increases the binding of peptidyl-tRNA with ribosomes, was antagonistic to the frameshifting defects of the most severe mutant, and the extent of sparsomycin resistance correlated with the severity of the frameshifting defects in all of the mutants. These results provide biochemical and physiological evidence that one function of L5 is to anchor peptidyl-tRNA to the P-site. A model is presented describing how decreased affinity of ribosomes for peptidyl-tRNA can affect both -1 and +1 frameshifting, and for the effects of sparsomycin.
authors.affiliation: Department of Molecular Genetics and Microbiology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, Piscataway 08854, USA.
authors.forename: A
authors.initials: A
authors.lastname: Meskauskas
authors.forename: J D
authors.initials: JD
authors.lastname: Dinman
mesh_terms: D000483:Alleles; D000841:Anisomycin / Q000494:pharmacology; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D016368:Frameshift Mutation; D009154:Mutation; D010458:Peptidyl Transferases / Q000037:antagonists & inhibitors; D010641:Phenotype; D010957:Plasmids / Q000378:metabolism; D014176:Protein Biosynthesis; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology; D012343:RNA, Transfer / Q000378:metabolism*; D018626:Retroelements / Q000235:genetics; D012269:Ribosomal Proteins / Q000737:chemistry*; D012270:Ribosomes / Q000378:metabolism; D012441:Saccharomyces cerevisiae / Q000378:metabolism*; D013033:Sparsomycin / Q000494:pharmacology; D013997:Time Factors
chemical_list: D000903:Antibiotics, Antineoplastic; D011500:Protein Synthesis Inhibitors; D018626:Retroelements; D012269:Ribosomal Proteins; C029742:ribosomal protein L5; D000841:Anisomycin; D013033:Sparsomycin; D012343:RNA, Transfer; D010458:Peptidyl Transferases